Epizyme hits the ground running with second — and crucial — OK for Tazverik, in follicular lymphoma
When Epizyme scored the first-ever approval for tazemetostat, in epithelioid sarcoma, execs made it clear it was only an appetizer, something to whet the appetites of regulators, investors and physicians to the potential of the methyltransferase inhibitor. Five months later, they are ready to serve the main course.
The biotech got all the help from the FDA to expand the label for Tazverik, going through priority review to land an accelerated approval in two indications of follicular lymphoma:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.